These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17402993)

  • 21. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.
    Khuroo MS; Khuroo MS; Dahab ST
    Aliment Pharmacol Ther; 2004 Nov; 20(9):931-8. PubMed ID: 15521839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.
    Martinot-Peignoux M; Comanor L; Minor JM; Ripault MP; Pham BN; Boyer N; Castelnau C; Giuily N; Hendricks D; Marcellin P
    J Viral Hepat; 2006 Oct; 13(10):701-7. PubMed ID: 16970602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
    Sánchez-Tapias JM; Crespo J; Diago M; Pérez R; Romero-Gómez M; Muñoz-Sánchez M
    Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):579-84. PubMed ID: 12616704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.
    D'Souza R; Main J; Crossey M; Rosenberg W; Murray-Lyon IM; Hayward C; Foster GR
    Aliment Pharmacol Ther; 2005 Jan; 21(1):43-7. PubMed ID: 15644044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Keeffe EB
    Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy.
    Angelico M; Cepparulo M; Angelico F; Francioso S; Barlattani A; Di Candilo F; Della Vecchia R; Demelia L; De Sanctis G; Gentile S; Grieco A; Parruti G; Sabusco G; Tarquini L; Tosti A; Zaru S;
    Aliment Pharmacol Ther; 2004 Feb; 19(3):339-47. PubMed ID: 14984381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive graphical model, network-based medical tool for the prognosis of chronic hepatitis C patients treated with peg-interferon plus ribavirin.
    Trapero-Marugan M; Marin M; Pivel JP; Del Rio JM; Nunez O; Clemente G; Gisbert JP; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Aug; 28(4):468-74. PubMed ID: 18549464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical management of a patient with drug dependence who attempted suicide while receiving peginterferon therapy for chronic hepatitis C.
    Fábregas BC; Moura AS; Marciano RC; Carmo RA; Teixeira AL
    Braz J Infect Dis; 2009 Oct; 13(5):387-90. PubMed ID: 20428642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of 8-nitroguanine in the liver of chronic hepatitis C patients without sustained virological response after completion of interferon therapy.
    Kaito M; Horiike S; Tanaka H; Fujita N; Adachi Y
    J Gastroenterol; 2006 Jul; 41(7):713-4. PubMed ID: 16933012
    [No Abstract]   [Full Text] [Related]  

  • 36. Extending our confidence in sustained virological response.
    Maan R; van der Meer AJ
    Liver Int; 2016 Jun; 36(6):794-7. PubMed ID: 26931778
    [No Abstract]   [Full Text] [Related]  

  • 37. Better design leads to better results - Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019.
    Zhaori G; Lu L; Liu C; Han S; Guo Y
    Pediatr Investig; 2023 Mar; 7(1):1-5. PubMed ID: 36967738
    [No Abstract]   [Full Text] [Related]  

  • 38. [New virological works and their importance for clinical practice].
    SHUBLADZE AK
    Klin Med (Mosk); 1961 Oct; 39():120-6. PubMed ID: 13912353
    [No Abstract]   [Full Text] [Related]  

  • 39. Performance of Virological Testing for Early Infant Diagnosis: A Systematic Review: Erratum.
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e64. PubMed ID: 28903128
    [No Abstract]   [Full Text] [Related]  

  • 40. SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
    Thorlund K; Druyts E; Mills EJ
    Clin Epidemiol; 2014; 6():49-58. PubMed ID: 24474846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.